Meng Yuan, Shu Xinyi, Yang Jie, Liang Yangyueying, Zhu Meiying, Wang Xuerui, Li Yue, Kong Fanming
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
Transl Lung Cancer Res. 2025 Feb 28;14(2):575-590. doi: 10.21037/tlcr-24-921. Epub 2025 Feb 18.
This article discusses new strategies for lung cancer organoids (LCOs) in precision medicine research. Precision medicine aims to identify and develop highly selective drugs targeted at specific disease markers for precise treatment. Given the genetic diversity among lung cancer cells, it is evident that different tumor cells may respond differently to various treatment regimens. LCOs can not only faithfully reproduce the pathological and genomic characteristics of samples, maintaining most variations, including driver gene mutations, but also preserve the cytological features of malignant tumor cells, showing a highly correlated in vitro drug screening response with the mutation spectrum in primary tumors. At this stage, several large-scale LCO biobanks have been established, providing ample sample resources for researchers. Based on this, the development of emerging technologies is expected to overcome limitations in the success rate, accuracy, and stability of the organoid culture process, significantly enhancing the level of precision medicine for lung cancer. This article mainly introduces the applications of LCO models in basic research, including the identification of drug targets, prediction of treatment efficacy, and overcoming drug resistance, assisting in the formulation of personalized treatment plans to improve treatment outcomes. Additionally, the article emphasizes the potential of cancer organoid co-culture models in the field of immunotherapy and their key role in advancing the evolution of precision medicine treatment strategies.
本文讨论了肺癌类器官（LCOs）在精准医学研究中的新策略。精准医学旨在识别和开发针对特定疾病标志物的高选择性药物，以实现精准治疗。鉴于肺癌细胞之间的基因多样性，不同的肿瘤细胞对各种治疗方案的反应可能不同，这一点显而易见。LCOs不仅可以忠实地再现样本的病理和基因组特征，保留包括驱动基因突变在内的大多数变异，还能保留恶性肿瘤细胞的细胞学特征，在体外药物筛选反应与原发性肿瘤的突变谱之间表现出高度相关性。现阶段，已经建立了几个大规模的LCO生物样本库，为研究人员提供了充足的样本资源。基于此，新兴技术的发展有望克服类器官培养过程中成功率、准确性和稳定性方面的限制，显著提高肺癌精准医学的水平。本文主要介绍了LCO模型在基础研究中的应用，包括药物靶点的识别、治疗效果的预测以及克服耐药性，协助制定个性化治疗方案以改善治疗效果。此外，本文强调了癌症类器官共培养模型在免疫治疗领域的潜力及其在推动精准医学治疗策略发展中的关键作用。
